PRESS RELEASE: Novo Nordisk: Total Voting Rights

Total number of voting rights and share capital in Novo Nordisk A/S 
as of 30 June 2009. 
 
 
In accordance with Section 6 of the Danish Statutory Order on Issuers 
Disclosure Obligations, Novo Nordisk is required to publish the total 
number of voting rights and the size of the share capital in Novo 
Nordisk as per the end of the month where changes have occurred. 
 
Referring to Company Announcement no 35/2009 dated 22 June 2009, 
please find below a statement regarding the total number of voting 
rights and share capital in Novo Nordisk as per 30 June 2009. 
 
 
+-------------------------------------------------------------------+ 
|          |     Number of shares | Nominal value | Number of votes | 
|          |       (nominal value |         (DKK) |                 | 
|          |               DKK 1) |               |                 | 
|----------+----------------------+---------------+-----------------| 
|          |                      |               |                 | 
| A shares |                      |   107,487,200 | 107,487,200,000 | 
|          |          107,487,200 |               |                 | 
|----------+----------------------+---------------+-----------------| 
|          |                      |               |                 | 
| B shares |                      |   512,512,800 |                 | 
|          |          512,512,800 |               |  51,251,280,000 | 
+-------------------------------------------------------------------+ 
 
 
Novo Nordisk is a healthcare company and a world leader in diabetes 
care. In addition, Novo Nordisk has a leading position within areas 
such as haemostasis management, growth hormone therapy and hormone 
replacement therapy. Novo Nordisk manufactures and markets 
pharmaceutical products and services that make a significant 
difference to patients, the medical profession and society. With 
headquarters in Denmark, Novo Nordisk employs more than 27,900 
employees in 81 countries, and markets its products in 179 countries. 
Novo Nordisk's B shares are listed on the stock exchanges in 
Copenhagen and London. Its ADRs are listed on the New York Stock 
Exchange under the symbol 'NVO'. For more information, visit 
novonordisk.com. 
 
For further information please contact: 
 
Media:                 Investors: 
 
Outside North America: Outside North America: 
Elin K Hansen          Mads Veggerby Lausten 
Tel: [phone]   Tel: [phone] 
[e-mail]    [e-mail] 
 
                       Kasper Roseeuw Poulsen 
                       Tel: [phone] 
                       [e-mail] 
 
In North America:      In North America: 
Sean Clements          Hans Rommer 
Tel: [phone] Tel: [phone] 
[e-mail]   [e-mail] 
 
 
Company Announcement 38 / 2009 
 
 
This announcement was originally distributed by Hugin. The issuer is 
solely responsible for the content of this announcement. 
 
http://hugin.info/2013/R/1325918/311960.pdf 
http://novonordisk.com 
Copyright © Hugin AS 2009. All rights reserved.